Surovatamig
Multispecific antibody
Evidence outlook · registrational
Follicular Lymphoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2031-11-26.
Also in development:Rheumatoid Arthritis · Phase 1Systemic Lupus Erythematosus · Phase 1Large B-Cell Lymphoma · Phase 3B-Cell Non-Hodgkin Lymphoma · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SOUNDTRACK-F1 NCT06549595 · Untreated Follicular Lymphoma Registry: NCT06549595 | 3 | SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs (Up to 10 years); SRI Primary: Determination of the recommended Phase III dose (RP3D) (Up to 1 year); Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy (Up to 10 years); Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy (Up to 10 years) 2031-11-26 | In progress: results expected 26 Nov 2031 | not yet graded | link ↗ |
View 1 more trial
RAZOR NCT07736950 · Follicular Lymphoma Registry: NCT07736950 | 3 | Event Free Survival (Time from date of randomisation until disease progression until end of 5 year follow up.); Event Free Survival (Time from date of randomisation to death from any cause, initiation of new anti-lymphoma treatment or disease progression until end of 10 year follow up. Assessment will be performed at end of treatment, every 3 months in year 1, every 6 months in year 2) 2035-01-13 | In progress: results expected 13 Jan 2035 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other CD19 x CD3 drugs
Blinatumomab, CLN-978, XmAb657. Compare all 4 CD19 x CD3 drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Surovatamig: this drug | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4512 | Phase 1/2 | Antibody–drug conjugate | CD22 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-88998377 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| REGN5837 | Phase 1 | Multispecific antibody | CD22 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3079 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb657 | Phase 1(overall) | Multispecific antibody | CD19 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Surovatamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.